Details of the Drug
General Information of Drug (ID: DMM4ZKU)
| Drug Name |
ZAPOTIN
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Zapotin; 14813-19-5; CHEMBL375582; 5,6,2',6'-tetramethoxyflavone; 2-(2,6-dimethoxyphenyl)-5,6-dimethoxychromen-4-one; Flavone, 2',5,6,6'-tetramethoxy-; AC1LCGQ2; SCHEMBL3307703; 2',6',5,6-Tetramethoxyflavon; DTXSID80348078; 2-(2,6-Dimethoxyphenyl)-5,6-dimethoxy-4H-chromen-4-one; PBQMALAAFQMDSP-UHFFFAOYSA-N; 2',5,6,6'-Tetramethoxyflavone; MolPort-005-945-165; 4H-1-Benzopyran-4-one, 2-(2,6-dimethoxyphenyl)-5,6-dimethoxy-; 5,6,2'',6''-tetramethoxyflavone; ZINC14756841; LMPK12110091; Flavone,2',5,6,6'-tetramethoxy-; BDBM50202558
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 342.3 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 3.1 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


